Provided by Tiger Trade Technology Pte. Ltd.

Arcus Biosciences Inc.

26.15
-2.3400-8.21%
Post-market: 26.150.00000.00%16:10 EDT
Volume:2.39M
Turnover:63.89M
Market Cap:3.33B
PE:-6.77
High:28.46
Open:28.02
Low:25.91
Close:28.49
52wk High:31.74
52wk Low:11.30
Shares:127.33M
Float Shares:89.84M
Volume Ratio:2.05
T/O Rate:2.66%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8641
EPS(LYR):-3.2900
ROE:-90.82%
ROA:-30.39%
PB:7.18
PE(LYR):-7.95

Loading ...

Analysts Offer Insights on Healthcare Companies: Brainsway (BWAY), Cooper Co (COO) and Arcus Biosciences (RCUS)

TIPRANKS
·
Yesterday

Arcus Biosciences Grants New Hire Options for 26,350 Shares, RSUs for 13,200 Shares

Reuters
·
Yesterday

Arcus Biosciences Price Target Raised to $40.00/Share from $35.00 by Truist Securities

Dow Jones
·
Sep 09

Arcus Biosciences, Inc. : Truist Securities Raises Target Price to $40 from $35

THOMSON REUTERS
·
Sep 08

Arcus Biosciences to Present at Citi 2026 Biotech Back to School Conference

Reuters
·
Aug 27

Arcus Biosciences Chief Accounting Officer Alexander Azoy Sells 2,827 Shares for $84,810

Reuters
·
Aug 25

What Arcus Biosciences (RCUS)'s Steep Revenue Drop and 2026 Guidance Cut Means For Shareholders

Simply Wall St.
·
Aug 16

Arcus Biosciences Memberi Hibah Induksi: Opsi 2.850 Saham Dan 1.450 RSU Untuk Karyawan Baru

Reuters
·
Aug 12

Arcus Biosciences' Casdatifan Therapy Could be Launched in 2028, Morgan Stanley Says

MT Newswires Live
·
Aug 11

Morgan Stanley Adjusts Price Target on Arcus Biosciences to $23 From $22, Maintains Equalweight Rating

MT Newswires Live
·
Aug 10

SIGA Technologies Q2 Revenue, Profit Drop as Contract Ends

Reuters
·
Aug 07

Arcus Biosciences Price Target Raised to $43.00/Share from $41.00 by Wedbush

Dow Jones
·
Aug 06

Wedbush Adjusts Price Target on Arcus Biosciences to $43 From $41, Maintains Outperform Rating

MT Newswires Live
·
Aug 06

Lexicon Pharmaceuticals Posts Q2 Net Loss

Reuters
·
Aug 06

Agenus Q2 Revenue Rises on Access and Royalty Income

Reuters
·
Aug 06

Arcus Biosciences, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Arcus Biosciences Q2 Revenue Falls Sharply on Lower License Income

Reuters
·
Aug 06

Arcus Biosciences Q2 FY26 Net Loss Widens to USD 91 Million; Revenue Drops 74.38% to USD 41 Million

Reuters
·
Aug 06

Arcus Biosciences Q2 EPS $(0.72) Beats $(0.87) Estimate, Sales $41.000M Beat $23.405M Estimate

Benzinga Earnings
·
Aug 06

Arcus Biosciences Q2 Pretax Profit USD -91 Million

Reuters
·
Aug 06